Study on Anagen effluvium - common side effect of chemotherapy

NewsGuard 100/100 Score

A new study published in the journal Dermatology shows that hair loss through anagen effluvium induced by chemotherapy manifests in patterns.

Specific scalp areas were shown to be resistant to chemotherapy, a fact not previously reported.

Anagen effluvium is a common side effect of chemotherapy, but few studies have examined its clinical characteristics. It is a type of hair loss that is characterized by hair breakage rather than hair loss.

Sixty-four patients with anagen effluvium were evaluated in this study. Chemotherapeutic agents were classified into 5 different groups. The pattern of hair loss was analyzed when specific involvement of the hairline was obvious.

Forty-six (71.9%) of the 64 total patients maintained hairs along their hairline. Hairs were maintained with a total hairline in 20 (31.3%), frontal hairline in 13 (20.3%) and occipital hairline in 12 (18.8%) patients. Among the 20 males with patterned hair loss, the following hairlines were preserved: occipital in 10 (50%), total in 7 (35%) and frontal in 3 (15%). Among the 25 females with patterned hair loss, hairlines were preserved as total in 13 (52%), frontal in 10 (40%) and occipital in 2 (8%). However, no significant differences were detected in hair loss patterns according to age, associated symptoms, chemotherapeutic agent group or combination of chemotherapeutic agents.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Novel approach uses patient's cells as "trojan horse" to target lung cancer cells